Company intelligence / Profile preview

Altria Ventures

Richmond, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Altria Ventures invests in companies developing innovative technologies and products that advance Altria's core businesses. The venture arm has focused investments in drug delivery platforms, particularly the DehydraTECH technology from Lexaria Bioscience, which demonstrates enhanced bioavailability for oral nicotine formulations and other active pharmaceutical ingredients.[2][3]

Therapeutic areas: PsychiatryCardiovascular
Modalities: Small moleculeDrug delivery technology platforms
Industry: Investors

Partnerships

Lexaria BioscienceKentucky BioProcessing (through parent company BAT connection)Oti-Topic (through parent company PMI connection)National Research Council of Canada (research collaboration on DehydraTECH)

Beyond the preview

Go deeper on Altria Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altria Ventures.

Explore the full profile